Browsing by Author Cathcart, A

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 3 to 7 of 7 < previous 
TitleAuthor(s)Issue DateViews
 
Longer treatment duration of monthly VIR-2218 results in deeper and more sustained reductions in hepatitis B surface antigen in participants with chronic hepatitis B infection. Oral Presentation (OS090)
Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology
Lim, YSYuen, RMFCloutier, DThanawala, VShen, LGupta, SVArizpe, ACathcart, AHwang, CGane, EJ
2022
 
Preliminary on-treatment data from a phase 2 study evaluating VIR-2218 in combination with pegylated interferon alfa-2a in participants with chronic hepatitis B infection
Proceeding/Conference:Journal of Hepatology
Yuen, RMFLim, YSCloutier, DShen, LArizpe, APang, PTay, CThanawala, VGupta, SVCathcart, AGane, E
2021
28
 
Preliminary results of a Phase 2 study of VIR-2218, an X-targeting RNAi therapeutic, in patients with chronic hepatitis B: sub-analyses of HBeAg-negative and HBeAg-positive patients
Proceeding/Conference:Hepatology International
Yuen, RMFLim, YSCloutier, DShen, LCathcart, ADing, XArizpe, APang, PHuang, SGane, E
2021
15
 
Safety and antiviral activity of VIR-2218, an X-targeting RNAi therapeutic, in participants with chronic hepatitis B infection: week 48 follow-up results
Proceeding/Conference:Journal of Hepatology
Gane, ELim, YSCloutier, DShen, LCathcart, ADing, XPang, PHuang, SYuen, RMF
2021
59
 
Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B
Proceeding/Conference:Hepatology
Chan, HLYLim, YSSeto, WKWAgarwal, KBrunetto, MRJanssen, HLACaruntu, FStepanova, TTsang, OYatsuhashi, HTak, WYChen, CYCelen, MSun, VFlaherty, JFLin, LCathcart, AGaggar, APan, CQShalimarButi, M
2018
384
Showing results 3 to 7 of 7 < previous